The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.
January 29th 2025
R. Lor Randall, MD, FACS, discusses the utility of routine intraoperative frozen section in soft tissue sarcomas and the impact of added costs.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Medical Crossfire®: Real World Strategies to Improve Therapeutic Durability and Outcomes in CLL
February 20, 2025
Register Now!
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases
View More
Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma
View More
Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies
View More
Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Avapritinib Approved in Europe for PDGFRA D842V–Mutant GIST
The European Commission has granted a conditional marketing authorization to avapritinib for single agent use in adult patients with unresectable or metastatic gastrointestinal stromal tumors that harbor a PDGFRA D842V mutation.
Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma
September 21st 2020The feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demonstrated in the phase 1b TRAMUNE trial.
Regorafenib Showed Modest Activity in Ewing Sarcoma
Regorafenib extended progression-free survival at 24 weeks compared with placebo for patients with Ewing sarcoma in the phase 2 REGOBONE study. However, the oral multi-kinase inhibitor failed to meet the study’s primary endpoint of non-progression at 8 weeks.
Dr. Roland on Findings From a Phase 2 Study With Neoadjuvant Checkpoint Blockade in Sarcoma
September 1st 2020Christina L. Roland, MD, MS, FACS, discusses the results from a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Experts Spotlight Ongoing Efforts Evaluating Immunotherapy in Sarcoma
August 21st 2020Despite encouraging data shown in some subtypes, there is still a lot of work that still needs to be done with determining the optimal use for immunotherapy in patients with sarcoma, a population that has historically been difficult to treat.
Randall Underscores the Need for Multidisciplinary Management of Desmoid Fibromatosis
August 21st 2020R. Lor Randall, MD, FACS, discusses the evolving management of desmoid fibromatosis, shares advice on the factors that go into deciding when to treat this disease, and stresses the importance of having a multidisciplinary team involved in the care of these patients.